TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$200 Million

Immunome, Inc.

Follow-on Offering

Bookrunner, February 2024

Immunome, Inc.

Immunome, Inc. (“Immunome” or the “Company”) (NASDAQ: IMNM) is a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies. The Company’s portfolio pursues each target with a modality appropriate to its biology, including antibody-drug conjugates, or ADCs; radioligand therapies, or RLTs; and immunotherapies. Immunome believes that pursuing underexplored targets with appropriate drug modalities leads to transformative therapies. Their proprietary memory B cell hybridoma technology allows for the rapid screening and functional characterization of novel antibodies and targets.